🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Citigroup Boosts Healthcare Strategy With Key Recruitments

Published 16/10/2023, 14:36
© Reuters.
C
-

Citigroup Inc (NYSE:C). has bolstered its healthcare dealmaking strategy amidst an economic downturn, according to an internal memo released on Monday. The banking giant has recruited former Credit Suisse banker Scott Bardo to serve as the managing director and head of medical technology, life sciences tools, and diagnostics for Europe, the Middle East, and Africa (EMEA). Bardo is set to commence his role from London starting January.

This strategic move aligns with Citigroup's 2021 plan of consolidating healthcare investment banking with consumer and retail divisions into a supergroup. The aim of this merger was to secure more mandates and strengthen the bank's position in the market.

In addition to Bardo's appointment, Citigroup has also enlisted Cyril Besseddik from JPMorgan Chase (NYSE:JPM) & Co. to lead coverage for EMEA healthcare firms. These new appointments reflect Citigroup's continued commitment to enhancing its healthcare strategy and improving its market standing amidst challenging economic conditions.

Citigroup, a prominent player in the Banks industry, has a market cap of 79.78B USD and trades at a low earnings multiple of 6.57, according to InvestingPro data. Despite some challenges, the company has maintained dividend payments for 13 consecutive years, a testament to its financial resilience. It's worth noting that the company's dividend yield as of 2023.D289 stands at 5.12%, reflecting its commitment to return capital to shareholders.

While the company has shown profitability over the last twelve months, InvestingPro Tips suggests that there could be some concerns regarding the company's earnings and cash flow. Notably, some analysts have revised their earnings downwards for the upcoming period. While this could potentially impact the company's financial performance, Citigroup's strategic moves in the healthcare sector could offset some of these challenges.

InvestingPro also provides a fair value estimate of 57.68 USD for Citigroup, higher than the analyst target of 47.5 USD. This could suggest a potential upside for the company's stock.

Citigroup's recent strategic moves and strong market position, coupled with its consistent dividend payments, make it a company worth considering for investors. For more insights and tips, consider exploring InvestingPro, which offers a wealth of additional tips and real-time metrics to help guide your investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.